Ocular Inflammation Treatment Market Size, Forecasts Report 2032

Ocular Inflammation Treatment Market Size – By Treatment Type (Corticosteroids, Antibiotics, Analgesics, Antivirals, Antifungals), By Indication, By Cause (Trauma & Injury, Autoimmune Diseases), By Route of Administration & Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Growing incidence of ocular inflammation and related complications

3.2.1.2&nbsp;&nbsp;&nbsp;Technological advancements

3.2.1.3&nbsp;&nbsp;&nbsp;Rising expenditure on the R&amp;D of novel treatments

3.2.1.4&nbsp;&nbsp;&nbsp;Increase in awareness of eye disorders

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Complications and adverse drug events related to medications

3.2.2.2&nbsp;&nbsp;&nbsp;Loss of patent protection for popular drugs

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.4.1&nbsp;&nbsp;&nbsp; Supplier power

3.4.2&nbsp;&nbsp;&nbsp; Buyer power

3.4.3&nbsp;&nbsp;&nbsp; Threat of new entrants

3.4.4&nbsp;&nbsp;&nbsp; Threat of substitutes

3.4.5&nbsp;&nbsp;&nbsp; Industry rivalry

3.5&nbsp;&nbsp;&nbsp; PESTEL analysis

3.6&nbsp;&nbsp;&nbsp; Reimburesemnt scenario

3.7&nbsp;&nbsp;&nbsp; Regulatory landscape

3.8&nbsp;&nbsp;&nbsp; Technological landscape

3.9&nbsp;&nbsp;&nbsp; Future market trends

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment Type, 2018 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Corticosteroids

5.3&nbsp;&nbsp;&nbsp; Antibiotics

5.4&nbsp;&nbsp;&nbsp; Analgesics

5.5&nbsp;&nbsp;&nbsp; Antivirals

5.6&nbsp;&nbsp;&nbsp; Antifungals

5.7&nbsp;&nbsp;&nbsp; Other treatment types

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2018 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Topical

6.3&nbsp;&nbsp;&nbsp; Oral

6.4&nbsp;&nbsp;&nbsp; Injectables

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Indication, 2018 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Uveitis

7.3&nbsp;&nbsp;&nbsp; Conjunctivitis

7.4&nbsp;&nbsp;&nbsp; Keratitis

7.5&nbsp;&nbsp;&nbsp; Scleritis

7.6&nbsp;&nbsp;&nbsp; Retinitis

7.7&nbsp;&nbsp;&nbsp; Other indications

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Cause, 2018 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Infectious causes

8.3&nbsp;&nbsp;&nbsp; Trauma and injury

8.4&nbsp;&nbsp;&nbsp; Autoimmune diseases

8.5&nbsp;&nbsp;&nbsp; Other causes

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2018 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

9.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; AbbVie Inc.

10.2&nbsp;&nbsp;&nbsp; Alimera Sciences

10.3&nbsp;&nbsp;&nbsp; Bausch Health Companies Inc.

10.4&nbsp;&nbsp;&nbsp; EyePoint Pharmaceuticals, Inc.

10.5&nbsp;&nbsp;&nbsp; Novartis AG

10.6&nbsp;&nbsp;&nbsp; Ocular Therapeutix, Inc.

10.7&nbsp;&nbsp;&nbsp; Pfizer Inc.

10.8&nbsp;&nbsp;&nbsp; Santen Pharmaceutical Co., Ltd. 
&nbsp;

Ocular Inflammation Treatment Market

Get a free sample of this report